- Home
- ESLA vs KPTI Comparison
ESLA vs KPTI Comparison
Compare ESLA & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | KPTI |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 36.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ESLA | KPTI |
|---|---|---|
| Price | $0.45 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 38.2K | ★ 1.4M |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $0.43 | $0.85 |
| 52 Week High | $3.15 | $10.99 |
Technical Indicators
Market Signals| Indicator | ESLA | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 17.66 |
| Support Level | N/A | N/A |
| Resistance Level | $0.85 | $2.16 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 8.81 | 4.23 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).